October 18, 2021

Tyrvaya™ (varenicline solution – Oyster Pharma) nasal spray 0.03mg has received U.S. FDA approval to treat the signs and symptoms of dry eye disease.

  • It is the first and only FDA-approved nasal spray for dry eye disease treatment.
  • The recommended dosing is one spray in each nostril twice daily, approximately 12 hours apart. Before initial use, the spray must be primed with seven actuations. It must be reprimed with one spray if not used for more than five days after initial priming.
  • Tyrvaya has launched at a wholesale acquisition cost (WAC) of $296.14 per bottle.
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More